Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

GSK, Ionis Pharmaceuticals win FDA approval for Hibsago (bepirovirsen) targeting hepatitis B virus in chronic hepatitis B infection following Ph3 success
Antisense oligonucleotide, infectious disease, hepatitis B, functional cure, combination therapy - Read more

Astellas Pharma, AI Proteins partner on computational miniprotein drug discovery, up to $400M
Research collaboration, AI/ML, drug discovery, small molecule, milestone payments - Read more

Okomera, Servier sign commercial agreement using tumor miniaturization technology for cancer research
Commercial agreement, oncology, tumor miniaturization, AI/ML, drug discovery - Read more

Vistagen, GATC Health collaborate to apply predictive AI across lead neuroscience clinical-stage drug programs
Research collaboration, AI/ML, neurological, drug discovery, small molecule - Read more

Visara secures exclusive option to acquire YOLO Immune's YOL104-2 for ocular surface squamous neoplasia
Acquisition option, ophthalmology, small molecule, milestone payments, royalties - Read more

Science 2 Sales is the outbound engine for companies selling into biotech & pharma. We handle the market intelligence, prospect scoring, email sequences, LinkedIn outreach, and cold calling - so your sales team inherits a full calendar of qualified meetings.

Built by biopharma BD & sales reps, exclusively for biopharma commercial teams. It’s the platform and service we wish we had years ago.

Learn more and book a free strategy call on our website.

Roche's fenebrutinib Ph3 data show reduced chronic brain inflammation in relapsing and primary progressive multiple sclerosis
Small molecule, neurological, BTK inhibitor, multiple sclerosis, monoclonal antibody, MOGAD - Read more

Priovant Therapeutics seeks label expansion for Lisraya (brepocitinib) after Ph3 success in non-infectious uveitis
Small molecule, autoimmune, JAK inhibitor, non-infectious uveitis, rare disease - Read more

Novo's CagriSema (cagrilintide/semaglutide) achieves 25% weight loss in women in Ph3 obesity trial
Small molecule, metabolic, GLP-1 receptor agonist, obesity, weight loss, women's health - Read more

F2G, Shionogi's (olorofim) meets Ph3 non-inferiority goal against AmBisome in invasive aspergillosis
Small molecule, infectious disease, antifungal, invasive aspergillosis, azole-refractory - Read more

Bioxodes BIOX-101 (BIOX-101) Ph2a data show significant reduction in perihematomal edema growth in intracerebral hemorrhage
Protein therapy, neurological, intracerebral hemorrhage, stroke, perihematomal edema, anti-inflammatory - Read more

Samsung Biologics wins court injunction blocking strike across nine core drug manufacturing stages
Biologics manufacturing, CDMO, operational, labor dispute - Read more

Biotech reverse mergers hit highest level since 2021, with 27 deals totaling $7.5B in 2026
Reverse merger, biopharma, financial, major transaction - Read more

Alcon acquires Neurotech Pharmaceuticals for $550M, gaining approved cell therapy Encelto for rare vision loss
Encapsulated cell therapy, rare disease, major transaction, strategic - Read more

OpenAI acquires Orchestra Bio, combining AI platforms to accelerate drug development workflows
AI drug development platform, drug discovery, strategic, major transaction - Read more

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

GSK terminates Ph1 trial of (GSK3965193), a PAPD5/PAPD7 inhibitor, for chronic hepatitis B infection
Antisense oligonucleotide, infectious disease, hepatitis B, PAPD5/PAPD7 inhibitor, chronic hepatitis B - Read more

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here